IMRN Overview

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.

Wall Street analysts forecast IMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Immuron Ltd revenue for the last quarter amounts to NaN USD, decreased

Immuron Ltd. EPS for the last quarter amounts to USD, decreased

Immuron Ltd (IMRN) has 7 emplpoyees as of April 21 2026.

Today IMRN has the market capitalization of 7.82M USD.